New Therapeutic Approaches Targeted at the Late Stages of the HIV-1 Replication Cycle
Keywords: Betulinic Acid Derivatives; Capsid; Epidemic; Gag; HIV-1; Inhibitors; Matrix; Nucleocapsid; RNA genome; UNAIDS/WHO; acyl chain; amino-acid; antiretroviral; antiviral; aromatic ring; assembly; binding affinity; bioavailability; budding; capsid antigen; causative agent; cell toxicity; covalent; cyclophilin; cytoplasmic; dimethylsuccinyl; disulfide bond; drug; drug-resistant HIV-1; encapsidation; enzymes; globular structure; glycineamide; glycoprotein; half-life; hexameric lattice; high-resolution structural; hydrophobic cavity; immunodeficiency; isolates; isoxazole; maturation; multimerization; multivesicular bodys; mutations; myristic acid; noninfectious; nucleocapsid; oxygen; peptides; phosphatidylinositol; phospholipids; polyprotein; rational drug; reduction; ribosomes; secondary screening; silicon; solubility; spectroscopy; sulfamide; tryptophan; vaccine; viral replication cycle; virology; virus infectivity; zinc-finger
Document Type: Research Article
Publication date: 2011-01-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.